Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis

doi:10.4239/wjd.v16.i5.103244

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (72)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=67

May 15, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Diabetes. May 15, 2025; 16(5): 103244
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.103244

Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis

Abul Bashar Mohammad Kamrul-Hasan, Vanishri Ganakumar, Lakshmi Nagendra, Deep Dutta, M Rafiqul Islam, Joseph M Pappachan

Abul Bashar Mohammad Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Bangladesh

Vanishri Ganakumar, Department of Endocrinology, Jawaharlal Nehru Medical College, Belagavi 590010, Karnataka, India

Lakshmi Nagendra, Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore 570015, Karnataka, India

Deep Dutta, Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi 110075, Delhi, India

M Rafiqul Islam, Department of Internal Medicine, Shaheed Suhrawardy Medical College Hospital, Dhaka 1207, Bangladesh

Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom

Joseph M Pappachan, Department of Endocrinology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, India

Author contributions: Kamrul-Hasan ABM and Dutta D were responsible for the conceptualization; Ganakumar V, Nagendra L, Dutta D, and Islam MR were responsible for the methodology; Kamrul-Hasan ABM and Nagendra L were responsible for the software; Dutta D and Pappachan JM were responsible for the validation; Kamrul-Hasan ABM and Islam MR were responsible for the formal analysis; Pappachan JM was responsible for the investigation; Kamrul-Hasan ABM, Ganakumar V, Nagendra L, Dutta D, Islam MR, and Pappachan JM were responsible for the resources; Kamrul-Hasan ABM was responsible for the data curation and project administration; Kamrul-Hasan ABM and Ganakumar V were responsible for the original draft preparation; Islam MR and Pappachan JM were responsible for the reviewing and editing; Nagendra L was responsible for the visualization; Pappachan JM was responsible for the supervision.

Conflict-of-interest statement: All authors have nothing to declare.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Joseph M Pappachan, MD, FRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, All Saints Building, Oxford Road, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in

Received: November 13, 2024
Revised: February 12, 2025
Accepted: February 25, 2025
Published online: May 15, 2025
Processing time: 163 Days and 11.7 Hours

Core Tip

Core Tip: This systematic review assessed available randomized controlled trials involving patients receiving beinaglutide, a short-acting glucagon-like polypeptide-1 receptor agonist. Beinaglutide at doses of 0.1-0.2 mg three times daily for 12-24 weeks was more effective than the control group at reducing body weight. Beinaglutide also demonstrated superiority over the control group in reducing body mass index and waist circumference. Beinaglutide posed greater risks of treatment discontinuation due to adverse events, including nausea, vomiting, palpitations, headaches, and dizziness, compared to the control group. However, the two groups had identical risks of total and serious adverse events, diarrhea, fatigue, and hypoglycemia.